Randomized trial finds targeting individual metastases in oligometastatic breast cancer does not improve survival
Treating individual metastatic tumors with highly focused radiation or surgery did not improve progression-free or overall survival for patients with oligometastatic breast cancer receiving first-line systemic therapy, according to results from the randomized NRG-BR002 clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
PrEP pill can prevent HIV, but partner reactions might stand in the way
United Kingdom
-
Combination therapy overcomes immunotherapy resistance in glioblastoma
United Kingdom
-
Shared family factors influence screen use and mental health problems in young people
United Kingdom
-
Study explains how sickle cell variant shapes malaria parasite infections
United Kingdom
-
More men living longer with incurable prostate cancer, report finds
United Kingdom
-
New SPARCS technology combines AI and microscopy to screen cells
United Kingdom
-
3D printing-inspired technology can improve dosing accuracy for personalized medicines
United Kingdom
-
Short-form video platforms trap users with ADHD in endless loops
United Kingdom